Scheduling Infusion & Delivery Services

Infusion coordination is handled by dedicated Prolastin Direct® Patient Services care coordinators. They can locate appropriate sites for infusions and coordinate all details, including scheduling infusion nurses, for you. All infusion nurses have access to specialized PROLASTIN-C training.

Pharmacy services with Prolastin Direct® Patient Services are handled by a staff of dedicated pharmacists at Dohmen Life Science Services who are on call 24 hours a day, every day. Services are customized for your needs, just as they are for each patient with Alpha-1.

Reliable delivery directly to any location of care is another service of Prolastin Direct® Patient Services. Based on the dosage schedule prescribed by your doctor, PROLASTIN-C is shipped automatically on a regular basis to the location where you'll receive your infusions. This ensures that you have PROLASTIN-C when and where you need it.

Home infusion services from Prolastin Direct® Patient Services enable scheduling flexibility and convenience for you and your family. This service provides home infusion by Alpha-1–certified nurses, who are provided through a national network of infusion nurses. Of course, we can also coordinate infusions in more traditional places, such as clinics and hospitals, if you and your doctor decide that is best.

Health management services from Prolastin Direct® Patient Services include education and supportive follow-up from AlphaNet Coordinators. All coordinators are patients with Alpha-1 themselves who have been specially trained to help other Alpha-1 patients like you.

KNOW THE STORY OF PROLASTIN DIRECT®

Find a Clinical Resource Center near you

There are over 50 Clinical Resource Centers in North America that specialize in patient care and education for patients with Alpha-1. Find the nearest Clinical Resource Centers by visiting the Alpha-1 Foundation Web site.


PROLASTIN®-C (alpha1-proteinase inhibitor [human]) is indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

The effect of augmentation therapy with any alpha1-proteinase inhibitor (alpha1-PI), including PROLASTIN-C, on pulmonary exacerbations and on the progression of emphysema in alpha1-antitrypsin deficiency has not been conclusively demonstrated in randomized, controlled clinical trials. Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C are not available.

PROLASTIN-C is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established.

PROLASTIN-C is contraindicated in IgA-deficient patients with antibodies against IgA due to the risk of severe hypersensitivity and in patients with a history of anaphylaxis or other severe systemic reactions to alpha1-PI.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. Should hypersensitivity symptoms be observed, promptly stop infusion and begin appropriate therapy. Have epinephrine and other appropriate therapy available for the treatment of any acute anaphylactic or anaphylactoid reaction.

PROLASTIN-C may contain trace amounts of IgA. Patients with known antibodies to IgA, which can be present in patients with selective or severe IgA deficiency, have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

The most common drug-related adverse reaction observed at a rate of >5% in subjects receiving PROLASTIN-C was upper respiratory tract infection. The most serious adverse reaction observed during clinical trials with PROLASTIN-C was an abdominal and extremity rash in 1 subject.

Because PROLASTIN-C is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

Please click here for full Prescribing Information for PROLASTIN-C.


References

  1. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha 1 antitrypsin deficiency. COPD. 2009;6(1):31-40.